196 results on '"Pohar, Kamal S."'
Search Results
2. Cystoscopy and Enhanced Diagnostics
3. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients
4. Roles of Androgen Receptor Signaling in Urothelial Carcinoma.
5. Penile cancer: Clinical Practice Guidelines in Oncology.
6. Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?
7. Blue Light Cystoscopy: Indications and Outcomes
8. Guideline-Based Management of Muscle-Invasive Bladder Cancer: NCCN, ICUD, and EAU
9. Periodically rotated overlapping parallel lines with enhanced reconstruction acquisition to improve motion-induced artifacts in bladder cancer imaging: Initial findings
10. Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?
11. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma
12. Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study
13. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study
14. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
15. E2f8 mediates tumor suppression in postnatal liver development
16. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
17. Bladder
18. Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma
19. Quality of Lymphadenectomy is Equivalent With Robotic and Open Cystectomy Using an Extended Template
20. Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients’ access to novel therapeutics.
21. Atezolizumab (atezo) with or without Bacille Calmette-Guérin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study.
22. Clinical Utility of Rigid Blue Light Cystoscopy: Results from a Post Procedure User Survey in a Prospective Multicenter Registry
23. Management of the urethra in the cystectomy patient
24. Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the gastrointestinal tract
25. How Do Commonly Performed Lymphadenectomy Templates Influence Bladder Cancer Nodal Stage?
26. Preoperative hydronephrosis as an indicator of survival after radical cystectomy
27. Guideline-Based Management of Muscle-Invasive Bladder Cancer: NCCN, ICUD, and EAU
28. Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy
29. EXPERT CONSENSUS DOCUMENT: Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
30. Challenges in the pathological reporting of urothelial carcinoma involving prostatic transurethral resection specimens within a single institution
31. Tomatoes, lycopene and prostate cancer: a clinician's guide for counseling those at risk for prostate cancer
32. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
33. RELATIONSHIP OF LYMPH NODE COUNT AND ACCURACY OF NODAL STAGE AT RADICAL CYSTECTOMY: 1046
34. A PROSPECTIVE COMPARISON OF INTRAOPERATIVE UROVYSION FISH AND URINARY CYTOLOGY: 192
35. Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis
36. Inflammatory myofibroblastic tumor of epididymis: a case report and review of literature
37. Urinary bladder chondroma
38. Management of Non-Muscle-Invasive Bladder Cancer: Practical Solutions for Common Problems.
39. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018
40. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma
41. Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?
42. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
43. Effect of GemRIS (gemcitabine-releasing intravesical system, TAR-200) on antitumor activity in muscle-invasive bladder cancer (MIBC).
44. A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection
45. Periodically rotated overlapping parallel lines with enhanced reconstruction acquisition to improve motion-induced artifacts in bladder cancer imaging: Initial findings.
46. E2f8 mediates tumor suppression in postnatal liver development
47. E2f8 mediates tumor suppression in postnatal liver development
48. Improving Bladder Cancer Imaging Using 3T Functional Dynamic Contrast-Enhanced MRI
49. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
50. Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.